Oslo, 6 January 2025: Reference is made to the stock exchange announcement
published by Circio Holding ASA (the "Company") on 19 December 2024, regarding
the final results of the warrant exercise for the 13,864,852 warrants (the
"Warrants"), issued in connection with the rights issue, where 12,921,088
Warrants were exercised, resulting in an aggregate subscription of 12,921,088
new shares in the Company ("New Shares"), and the stock exchange announcement
published on 18 December 2024 regarding completion of a private placement of
4,903,925 new shares (the "Private Placement").

The share capital increases related to the warrants exercise and the Private
Placement have been registered with the Norwegian Register of Business
Enterprises today, 6 January 2025. The Company's new share capital is NOK
42,090,397.20 divided into 70,150,662 shares, each with a nominal value of NOK
0.60.

The new shares related to the warrant exercise and the Private Placement will,
following the registration of the share capital increases, be issued and
delivered as soon as practically possible.

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

Lubor Gaal, CFO
Phone: +34 683343811
Email: lubor.gaal@circio.com

About Circio

Building next generation RNA technology for nucleic acid medicine

Circio Holding ASA is a biotechnology company developing powerful circular RNA
vector expression technology for next generation nucleic acid medicine.

Circio has established a unique circular RNA (circRNA) vector expression
platform for novel DNA, RNA and viral therapeutics. The proprietary circVec
technology is based on a modular genetic cassette design for efficient
biogenesis of multifunctional circRNA inside cells, which can be deployed in
multiple therapeutic settings, including genetic medicine, cell therapy and
chronic disease. The circVec platform has demonstrated up to 15-fold enhanced
and more significantly more durable protein expression vs. classic mRNA vector
systems and has the potential to become a new gold-standard platform technology
for nucleic acid and viral therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.

In addition, Circio is developing a pan-RAS cancer vaccine, TG01, targeting KRAS
driver mutations. TG01 is currently being tested in two clinical trials: RAS
-mutated pancreatic and lung cancer in the USA and multiple myeloma in Norway.
These studies are being run through academic and industry collaborative
networks, supported by prestigious research grants from Innovation Norway and
the Norwegian Research Council, creating read-outs and future optionality for
the program at low cost to Circio.